Skip to main content
Sign In

Dan Theodorescu, MD, PhD

Cancer Center Director

Current Position 

Paul A. Bunn, Jr. Endowed Chair in Cancer Research 

Professor of Surgery and Pharmacology 

Director, University of Colorado Comprehensive Cancer Center 

Education & Training 

• MD, Queen's University, Kingston, Ontario, Canada 

 • PhD, University of Toronto, Ontario, Canada 

• Residency in Urology: University of Toronto 

• Fellowship in Urologic Oncology: Memorial Sloan-Kettering Cancer Center Program 

Recognition & Awards 

• Elected to National Academy of Medicine 

• Barringer Medal for Outstanding Contributions, American Association of Genitourinary Surgeons 

• Elected to American Surgical Association (ASA) 

• Inventor of the Year, University of Colorado 

• Elected to American Association of Genitourinary Surgeons (AAGUS) 

• Elected to American Society for Clinical Investigation (ASCI) 

• Edwin Beer Award, New York Academy of Medicine 

 • Young Investigator Award, Society for Basic Urologic Research (SBUR) 

• Kimmel Foundation Scholar 

Editorial Responsibilities 

• Co-Editor in Chief, Bladder Cancer​, the first journal focusing on this field. 

• Editorial Board, Cancer Research ​

• Past Co-Editor in Chief, World Journal of Urology 

Research Program Description

Working on a disease that has seen few advances in the last 30 years, Theodorescu has emerged as a leading translational bladder cancer researcher. Theodorescu is known for his work on the molecular mechanisms underlying bladder cancer and tools that determine drug response as well as discovery of new drugs for several cancer types. Examples include discovery of genes that regulate tumor growth and metastasis (RhoGDI2, CD24, AGL, GON4L) in bladder and other cancers and novel biomarkers (DNA/NGS, RNA and proteomic) and concepts for precision therapeutic approaches such as the COXEN principle, that are currently being tested in national (SWOG) clinical trials. He led the discovery and development of a “first in class” RalGTPase inhibitor as a new therapeutic in several human cancer types which is now in commercial development. Recent efforts in our lab have focused on understanding the biology of Telomerase reverse transcriptase (TERT) and using that knowledge to develop novel inhibitors to this critical protein in cancer. Finally, active efforts are currently aimed at identifying immune system agonists or antagonists that modulate tumor behavior in vivo as well as the identification of novel combination therapies that enhance the effectiveness of checkpoint and other immunotherapy. ​​

Affiliated Programs

​Pharmacology Program​​